KR101017556B1 - Health food compositions included taheebo, champignon and mulberry leaves - Google Patents
Health food compositions included taheebo, champignon and mulberry leaves Download PDFInfo
- Publication number
- KR101017556B1 KR101017556B1 KR1020080069867A KR20080069867A KR101017556B1 KR 101017556 B1 KR101017556 B1 KR 101017556B1 KR 1020080069867 A KR1020080069867 A KR 1020080069867A KR 20080069867 A KR20080069867 A KR 20080069867A KR 101017556 B1 KR101017556 B1 KR 101017556B1
- Authority
- KR
- South Korea
- Prior art keywords
- group
- champinion
- tahibo
- powder
- concentration
- Prior art date
Links
- 240000000249 Morus alba Species 0.000 title claims abstract description 54
- 235000008708 Morus alba Nutrition 0.000 title claims abstract description 54
- 235000013402 health food Nutrition 0.000 title claims abstract description 13
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- 235000001674 Agaricus brunnescens Nutrition 0.000 title description 3
- 244000251953 Agaricus brunnescens Species 0.000 title description 2
- 239000010233 Taheebo Substances 0.000 title description 2
- 239000000843 powder Substances 0.000 claims abstract description 31
- 239000002361 compost Substances 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 4
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000003306 harvesting Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 235000021190 leftovers Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000002156 mixing Methods 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 7
- 229910021529 ammonia Inorganic materials 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 239000004202 carbamide Substances 0.000 description 7
- 239000011777 magnesium Substances 0.000 description 7
- 229910052749 magnesium Inorganic materials 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 229910052802 copper Inorganic materials 0.000 description 6
- 239000010949 copper Substances 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 229910052725 zinc Inorganic materials 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- 229910052793 cadmium Inorganic materials 0.000 description 5
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 240000000111 Saccharum officinarum Species 0.000 description 3
- 235000007201 Saccharum officinarum Nutrition 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 235000019645 odor Nutrition 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 235000005523 excessive nutrition Nutrition 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000011133 lead Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 타히보 분말, 샴피니온 분말, 뽕잎 분말을 배합하여 제조된 건강식품 조성물에 관한 것으로서, 타히보 분말 20∼50 중량부와 샴피니온 분말 20∼50 중량부 및 뽕잎 분말 20∼50 중량부를 배합하여 제조된다.The present invention relates to a health food composition prepared by combining Tahibo powder, champinion powder, and mulberry leaf powder, 20 to 50 parts by weight of Tahibo powder, 20 to 50 parts by weight of champinion powder and 20 to 50 parts by weight of mulberry leaf powder. It is prepared by blending.
Description
본 발명은 타히보, 샴피니온 및 뽕잎을 주원료로 하여 제조된 건강식품 조성물에 관한 것이다. 따라서 본 발명의 건강식품 조성물에는 자연스럽게 타히보, 샴피니온 및 뽕잎의 성분이 고루 함유되어 있다.The present invention relates to a health food composition prepared using Tahibo, champinion and mulberry leaves as main ingredients. Therefore, the health food composition of the present invention naturally contains the components of Tahibo, champinion and mulberry leaves.
우리 인간의 건강 상태는 음식물과 밀접한 관계를 가지고 있다.The health of our humans is closely related to food.
70년대 후반부터 소득 향상과 더불어 식생활이 서구화되면서 육식이 급속도로 늘어나면서 그간 채식을 주로 하여 왔던 과거에는 별로 없던 각종 성인병이 급격히 증가되어 이제는 사회문제로까지 대두되게 되었다. 즉, 동물성 지방식품이나 가공식품, 인스턴트식품 및 각종 식품첨가물의 섭취량이 급증하였으므로 장내(腸內) 환경이 나빠지게 되었고 그 결과 평균 수명이 크게 늘었음에도 불구하고 인간 본래의 면역력이 저하되어 비만, 고혈압, 당뇨, 고지혈증 등 각종 질병에 걸리기 쉽게 되었다. In the late 1970s, as incomes increased and westernized eating became more rapid, meat eating rapidly increased, and various kinds of adult diseases, which had been mainly vegetarian, have increased rapidly. In other words, the intake of animal fats, processed foods, instant foods, and various food additives increased rapidly, resulting in worsening of the intestinal environment. , Diabetes, hyperlipidemia and other diseases are susceptible.
그 결과 식생활에 대한 반성과 더불어 건강에 대한 관심이 어느 때보다 높아졌으 며, 이에 따라 성인병을 예방할 수 있는 건강식품에 대한 요구도 크게 늘고 있다. As a result, interest in health is higher than ever, and the demand for health foods that can prevent adult diseases is increasing.
본 발명은 타히보 분말과 샴피니온 분말 및 뽕잎 분말을 주원료로 하여 제조된 건강식품 조성물에 관한 것으로서 동물성 지방식품의 과다 섭취로 인한 영양 과잉으로 사회 문제가 되고 있는 메타보릭 신드럼의 개선과 다이어트에 큰 효과가 있는 건강식품 조성물에 관한 것이다. The present invention relates to a health food composition prepared using Tahibo powder, championion powder, and mulberry leaf powder as main ingredients, and to improving and dieting metabolic synthrum, which is a social problem due to excessive nutrition of animal fat foods. It relates to a health food composition having a great effect.
본 발명의 건강식품 조성물에는 타히보, 샴피니온 및 뽕잎의 성분이 고루 함유되어 있으므로 꾸준히 복용하면 구취, 체취 및 노인취(老人臭)를 예방할 수 있고 또 당뇨병, 고혈압, 고지혈증, 비만 등 성인병의 예방과 소화관장증을 예방하는데 큰 역할을 함은 물론 항균능력 및 면역력을 증진시킬 수 있다. Since the health food composition of the present invention contains the components of Tahibo, champinion and mulberry leaves evenly, if taken steadily to prevent bad breath, body odor and elderly odor (老人 臭) and also prevent the adult diseases such as diabetes, hypertension, hyperlipidemia, obesity In addition to playing a large role in the prevention of digestive enemas, as well as to enhance the antimicrobial and immunity.
본 발명은 타히보 분말, 샴피니온 분말, 뽕잎 분말을 배합하여 제조된 건강식품 조성물에 관한 것이다.The present invention relates to a health food composition prepared by combining Tahibo powder, champinion powder, mulberry leaf powder.
타히보(Taheebo)는 남미 아마존에 자생하는 나무로서 현지에서는 기적의 약목(藥木)이라고 불리고 있다. 타히보에는 살균력이 있어 수목에는 벌레도 붙지 않고 곰팡이도 나지 않는다고 한다.Taheebo is a tree native to the South American Amazon and is called the miracle of miracles locally. It is said that Tahibo has bactericidal properties, so that trees do not have insects or mold.
타히보의 약리작용으로는 신진대사를 활발히 하고, 해독, 발한, 혈액 정화 및 혈액순환촉진, 각질화된 피부 세포의 교체를 촉진, 신선한 혈액생산, 지방 흡수도와 세 포 활동의 최적조건제시, 노화방지, 배뇨촉진, 당뇨 예방 및 치료 등에 효과가 있는 것으로 알려져 있다..Tahibo's pharmacological actions include active metabolism, detoxification, sweating, blood purification and blood circulation, facilitation of exfoliation of keratinized skin cells, fresh blood production, suggesting optimal conditions for fat absorption and cell activity, anti-aging, It is known to be effective in promoting urination, preventing and treating diabetes.
본 발명에서는 타히보 분말 20∼50 중량부를 배합하였다.In the present invention, 20 to 50 parts by weight of tahibo powder is blended.
샴피니온(Champignon)은 서양 버섯의 일종이며, 장내 환경에 있어 선균(善菌)을 늘리고 악균을 줄이는 작용을 하고, 장내 및 혈액 중의 유해 악취물질을 중화시키는 능력이 있어 악취 등 각종 냄새를 제거하는 데 효과가 있다.Champignon is a type of Western mushroom, which increases intestinal bacteria and reduces bad bacteria in the intestinal environment, and has the ability to neutralize harmful odorous substances in the intestine and blood to remove various odors. Effective at
샴피니온 종균을 배양하는 배지(菌床)는 사탕수수를 짜고 남은 찌꺼기 또는 콩을 짜고 남은 찌꺼기를 원료로 하여 제조하였다. The culture medium for cultivating the champinion spawn was prepared by squeezing sugar cane or remaining squeezed beans and raw waste.
샴피니온 분말을 제조하는 공정은 다음과 같다.The process for preparing the champinion powder is as follows.
우선 사탕수수를 짜고 남은 찌꺼기 또는 콩을 짜고 남은 찌꺼기를 60 ~ 90일간 퇴비를 생산한 후 상기 퇴비에 샴피니온균을 주입하여 30 ~ 50일간 배양한다. 이어 성숙된 샴피니온을 채취하여 물로 세척한 후 2 ~ 5cm 크기로 절단한다. 상기 크기로 절단된 샴피니온을 건조기로 이송하여 45 ~ 55℃로 8 ~ 12시간 건조시킨다. 상기 건조된 샴피니온을 분쇄기로 이송하여 1.5mm의 분말로 분쇄한다. First, squeeze sugar cane and the remaining residue or beans squeeze the remaining residue to produce 60 to 90 days of compost and incubate for 30 to 50 days by injecting the champinion bacteria to the compost. Then, mature champinions are taken, washed with water, and cut into 2-5 cm. The champignion cut to the size is transferred to a dryer and dried at 45 to 55 ° C. for 8 to 12 hours. The dried champinion is transferred to a grinder and ground to a powder of 1.5 mm.
본 발명에서는 샴피니온 분말 20∼50 중량부를 배합하였다.In the present invention, 20 to 50 parts by weight of champinion powder is blended.
뽕잎은 한마디로 성인병의 종합 예방제인 동시에 치료제로 상당한 기능을 가지고 있다. In short, mulberry leaves have a significant function as a comprehensive preventive and therapeutic agent for adult diseases.
뽕잎에는 글루코사이드, 비타민 C, B1, B2 등 100여종 이상의 좋은 성분이 포함되어 있다. 뽕잎은 단백질 함량이 잎파리 중에서 가장 높다. 그뿐만 아니라 뽕잎에는 미네랄이 풍부하게 들어 있고, 각종 비타민, 아미노산, 섬유소가 풍부하게 들어 있다. 특히 뽕의 잎 특유의 성분인 1-디옥시노지리마이신(DNJ, deoxynojirimycin)을 함유하고 있어 당분을 분해하는 효소와 특히 급격한 혈당량 상승을 억제한다. 또 뽕잎 속에는 뇌 속의 피를 잘 돌게 하고 콜레스테롤을 제거하고 노인성 치매를 예방해 주는 세린과 타이로신 성분이 각각 1.2%와 0.8% 들어 있다. Mulberry leaves contain more than 100 good ingredients such as glucoside, vitamin C, B1, B2. Mulberry leaves have the highest protein content among leaf flies. In addition, mulberry leaves are rich in minerals, rich in vitamins, amino acids, and fiber. In particular, it contains 1-deoxynojirimycin (DNJ, deoxynojirimycin), which is a unique ingredient of mulberry leaves, and inhibits sugar breakdown and particularly rapid blood sugar rise. The mulberry leaves also contain 1.2% and 0.8% of serine and tyrosine, respectively, which help to spin blood in the brain, remove cholesterol and prevent senile dementia.
이 밖에도 혈압을 내려 주는 성분(가바), 뇌혈관을 튼튼하게 해 주는 성분(루틴), 그리고 혈관에 붙어 있는 기름덩이를 없애 주는 작용, 동맥경화를 없애는 주는 작용이 밝혀지고 있다. In addition, the blood pressure-lowering component (Gabba), the cerebrovascular component (rutin), and the blood vessels attached to remove the oil, the arteriosclerosis is being removed.
본 발명에서는 뽕잎 분말 20∼50 중량부를 배합하였다In the present invention, 20 to 50 parts by weight of mulberry leaf powder is blended.
따라서 본 발명의 건강식품 조성물은 타히보 분말 20 ∼50 중량부, 샴피니온 분말 20 ∼50 중량부, 뽕잎 분말 20 ∼50 중량부를 배합하여 제조된다. Therefore, the health food composition of the present invention is prepared by combining 20-50 parts by weight of tahibo powder, 20-50 parts by weight of champinion powder, and 20-50 parts by weight of mulberry leaf powder.
실시예 1Example 1
1. 생후 6주령의 쥐를 아무 것도 투여하지 않는 Control군, 뽕잎만 투여하는 뽕잎 군, 타히보만 투여하는 타히보 군, 샴피니온만 투여하는 샴피니온 군 및 타히보·샴피니온·뽕잎을 동일 비율로 투여하는 배합군으로 분류하고 3주간 격일로 소정 물질을 경구 투여한 후 혈액을 채취하여 항산화 작용을 측정하였다. 1.The same control group does not administer any 6-week-old rats, the mulberry leaf group administers only the mulberry leaves, the Tahibo group administers only Tahibo, the champinion group administers only championes, and the Tahibo / championion / mulberry leaves. It was classified as a compounded group administered at a ratio and orally administered a predetermined substance every three weeks, and then blood was collected to measure antioxidant activity.
한편 60일간 격일로 소정 물질을 경구 투여한 후 혈액으로부터 요소, 유산, 암모니아 농도를, 소변으로부터 금속원소의 농도를 액체 크로마토그래피(Chromatography)로 검사하여 해독 효과를 측정하였다. Meanwhile, after oral administration of a predetermined substance every other day for 60 days, the concentration of urea, lactic acid, ammonia from blood, and the concentration of metal elements from urine were examined by liquid chromatography (Chromatography) to determine the detoxification effect.
2. 채취한 혈액을 원심 분리하여 얻은 혈청에 대하여 루미놀(Luminol) 측정과 SOD 활성도를 측정하여 항 산화 작용에 대한 결과를 얻었고, 혈액을 원심 분리하여 얻은 혈청과 소변(尿)을 액체 크로마토그래피로 검사하여 해독효과를 측정하였다. 2. The serum obtained by centrifugation of the collected blood was measured for luminol and SOD activity, and the results of antioxidant activity were obtained. The serum and urine obtained by centrifugation of blood were analyzed by liquid chromatography. Examination to determine the detoxification effect.
2. 항산화 효과2. Antioxidant effect
2-1. 루미놀 측정 결과 2-1. Luminol measurement result
세로축에 측정한 발광 강도를 나타내고, 투여 60일 후의 Control군, 뽕잎 군, 타히보 군, 샴피니온 군 및 배합군의 혈청에 있어서의 퍼락시 래디칼(Peroxy Radical)에 대한 스카벤징(Scarvenging) 작용의 결과를 도 1에 나타내었다. The luminescence intensity measured on the vertical axis is shown, and the scavenging effect on the Peroxy Radical in the serum of the Control group, Mulberry leaf group, Tahibo group, Champignion group and combination group after 60 days of administration. The results are shown in FIG.
도 1에서 보는 바와 같이 Control군의 발광 강도와 비교해 뽕잎 군, 타히보 군, 샴피니온 군 특히 배합군의 발광 강도 감소가 현저하였다. 따라서 모든 투여군 특히 배합군에게 퍼락시래디칼 스카벤징 작용을 기대할 수 있음을 알 수 있다.As shown in FIG. 1, the decrease in the emission intensity of the mulberry leaf group, the Tahibo group, the champinion group, and especially the combination group was remarkable compared to the emission intensity of the Control group. Therefore, it can be seen that all the administration groups, especially the combination group, can be expected to the paraxir radical scavenging action.
2-2. SOD 활성도 2-2. SOD activity
세로축에 측정한 SOD 활성도(%)를 나타내고, 투여 60일 후의 Control군, 뽕잎 군, 타히보 군, 샴피니온 군 및 배합군의 혈청에 있어서의 래디칼에 대한 항산화 작용의 결과를 도 2에 나타내었다. The SOD activity (%) measured on the vertical axis is shown, and the result of the antioxidant activity to the radical in the serum of the control group, mulberry leaf group, tahibo group, champinion group and
도 2에서 보는 바와 같이 Control군의 SOD 활성도와 비교해 뽕잎 군, 타히보 군, 샴피니온 군 특히 배합군의 SOD 활성도 증가가 현저하였다. 따라서 모든 투여군에 대한 항산화 작용을 기대할 수 있고 특히 배합군에는 항산화 작용에 상승효과가 있는 것을 알 수 있다.As shown in Figure 2, compared with the SOD activity of the control group, the increase in SOD activity of the mulberry leaf group, Tahibo group, champinion group, especially the combination group was remarkable. Therefore, anti-oxidation effect can be expected for all the administration groups, and especially in the combination group, it can be seen that there is a synergistic effect on the antioxidant action.
2-3. 혈 중의 요소, 유산, 암모니아 등의 농도2-3. Concentrations of urea, lactic acid and ammonia in the blood
2-3-1. 혈 중의 요소농도2-3-1. Urea Concentration in Blood
투여 60일 후의 Control군, 뽕잎 군, 타히보 군, 샴피니온 군 및 배합군의 혈 중의 요소농도의 결과를 도 3에 나타내었다. The results of the blood urea concentration of the control group, mulberry leaf group, Tahibo group, champinion group and the
도 3에서 보는 바와 같이 Control군과 비교해 뽕잎 군, 타히보 군, 샴피니온 군의 혈 중의 요소농도 저하가 인정되었으며 특히 배합군의 혈 중의 요소농도 저하가 현저하였다. As shown in FIG. 3, the blood urea concentration was lowered in the mulberry leaf group, the Tahibo group, and the champinion group as compared to the control group, and in particular, the blood urea concentration was lowered in the combination group.
2-3-2. 혈 중의 유산농도2-3-2. Lactic acid concentration in the blood
투여 60일 후의 Control군, 뽕잎 군, 타히보 군, 샴피니온 군 및 배합군의 혈 중의 유산농도의 결과를 도 4에 나타내었다. The results of the lactic acid concentration in the blood of the control group, mulberry leaf group, Tahibo group, champinion group and
도 4에서 보는 바와 같이 Control군과 비교해 뽕잎 군, 타히보 군, 샴피니온 군, 배합군의 혈 중의 유산농도 저하가 인정되었다. As shown in Figure 4 compared with the control group mulberry leaf group, Tahibo group, champinion group, lowering the lactic acid concentration in the blood of the combination group was recognized.
2-3-3. 혈 중의 암모니아농도2-3-3. Ammonia Concentration in Blood
투여 60일 후의 Control군, 뽕잎 군, 타히보 군, 샴피니온 군 및 배합군의 혈 중의 암모니아농도의 결과를 도 5에 나타내었다. The results of ammonia concentrations in the blood of the control group, mulberry leaf group, tahibo group, champinion group and the
도 5에서 보는 바와 같이 Control군과 비교해 뽕잎 군, 타히보 군, 샴피니온 군의 혈 중의 암모니아농도 저하가 인정되었으며 특히 배합군의 혈 중의 암모니아농도 저하가 현저하였다. As shown in Figure 5 compared with the control group mulberry leaf group, Tahibo group, champinion group was recognized a decrease in blood ammonia concentration, especially in the blood group ammonia concentration decrease was significant.
2-3-4. 소변에 의한 금속원소(동, 납, 아연, 마그네슘, 카드뮴, 나트륨)의 검사 결과 2-3-4. Test result of metal element (copper, lead, zinc, magnesium, cadmium, sodium) by urine
2-3-4-1. 소변에 의한 동의 농도2-3-4-1. Concentration of copper by urine
투여 60일 후의 Control군, 뽕잎 군, 타히보 군, 샴피니온 군 및 배합군의 소변에 의한 동의 농도의 결과를 도 6에 나타내었다. The results of the concentration of copper by the urine of the control group, mulberry leaf group, Tahibo group, champinion group and the
도 6에서 보는 바와 같이 Control군의 소변 중의 동의 농도와 비교해 뽕잎 군, 타히보 군, 샴피니온 군에서는 별 차이가 없었다. 그러나 배합군에서는 동 농도의 저하가 인정되었다. As shown in FIG. 6, the mulberry leaf group, the Tahibo group, and the champinion group did not differ significantly compared to the concentration of copper in the urine of the Control group. However, in the blended group, a decrease in copper concentration was recognized.
2-3-4-2. 소변에 의한 납의 농도2-3-4-2. The concentration of lead by urine
투여 60일 후의 Control군, 뽕잎 군, 타히보 군, 샴피니온 군 및 배합군의 소변에 의한 납의 농도의 결과를 도 7에 나타내었다. The results of the concentration of lead in the urine of the control group, mulberry leaf group, Tahibo group, champinion group and
도 7에서 보는 바와 같이 Control군의 소변 중의 납의 농도와 비교할 때 뽕잎 군, 타히보 군, 샴피니온 군에서 낮았음을 알 수 있었고 특히 배합군의 경우 납 농도가 가장 낮았다. As shown in FIG. 7, it was found that the mulberry leaf group, the Tahibo group, and the champinion group were lower than the lead concentration in the urine of the control group, and in particular, the lead group was the lowest.
2-3-4-3. 소변에 의한 아연의 농도2-3-4-3. Concentration of zinc by urine
투여 60일 후의 Control군, 뽕잎 군, 타히보 군, 샴피니온 군 및 배합군의 소변에 의한 아연의 농도의 결과를 도 8에 나타내었다. Results of the concentration of zinc in the urine of the control group, mulberry leaf group, tahibo group, champinion group and combination group after 60 days of administration are shown in FIG. 8.
도 8에서 보는 바와 같이 Control군의 소변 중의 아연의 농도와 비교할 때 뽕잎 군, 타히보 군, 샴피니온 군에서 낮았음을 알 수 있었고 특히 배합군의 경우 아연 농도가 가장 낮았다. As shown in FIG. 8, when compared with the concentration of zinc in the urine of the control group, it was found that the mulberry leaf group, Tahibo group, champinion group was low, especially in the combination group was the lowest zinc concentration.
2-3-4-4. 소변에 의한 카드뮴의 농도2-3-4-4. Concentration of cadmium by urine
투여 60일 후의 Control군, 뽕잎 군, 타히보 군, 샴피니온 군 및 배합군의 소변에 의한 마그네슘의 농도의 결과를 도 9에 나타내었다. The results of the concentration of magnesium in the urine of the control group, mulberry leaf group, Tahibo group, champinion group and the
도 9에서 보는 바와 같이 Control군의 소변 중의 카드뮴의 농도와 비교할 때 뽕잎 군, 타히보 군, 샴피니온 군에서 낮았음을 알 수 있었고 특히 배합군의 경우 카드뮴 농도가 가장 낮았다. As shown in FIG. 9, the concentration of cadmium in the urine of the Control group was low in the mulberry leaf group, Tahibo group, and the champinion group, and especially in the combination group, the cadmium concentration was the lowest.
2-3-4-5. 소변에 의한 마그네슘의 농도2-3-4-5. Concentration of magnesium by urine
투여 60일 후의 Control군, 뽕잎 군, 타히보 군, 샴피니온 군 및 배합군의 소변에 의한 마그네슘의 농도의 결과를 도10에 나타내었다. The results of the concentration of magnesium in the urine of the control group, mulberry leaf group, tahibo group, champinion group and the
도 10에서 보는 바와 같이 Control군의 소변 중의 마그네슘의 농도와 비교할 때 뽕잎 군, 타히보 군에서 낮았음을 알 수 있었고 특히 샴피니온 군과 배합군의 경우 마그네슘 농도가 더욱 낮았다. As shown in FIG. 10, it was found that the mulberry leaf group and the Tahibo group were lower than the magnesium concentration in the urine of the control group. In particular, the magnesium concentration was lower in the champinion group and the combination group.
2-3-4-5. 소변에 의한 나트륨의 농도2-3-4-5. Concentration of sodium by urine
투여 60일 후의 Control군, 뽕잎 군, 타히보 군, 샴피니온 군 및 배합군의 소변에 의한 나트륨의 농도의 결과를 도 11에 나타내었다. The results of the concentration of sodium in the urine of the control group, mulberry leaf group, tahibo group, champinion group and the
도 11에서 보는 바와 같이 Control군의 소변 중의 나트륨의 농도와 비교할 때 뽕잎 군, 타히보 군에서는 별 차이가 없었으나 샴피니온 군의 경우 나트륨 농도가 낮았고 배합군의 경우 나트륨 농도가 가장 낮았다..As shown in FIG. 11, the mulberry leaf group and the Tahibo group showed no difference when compared with the sodium concentration in the urine of the control group, but the sodium concentration was low in the champinion group and the lowest sodium concentration in the combination group.
이상 실시예에서 보는 바와 같이 발명은 타히보 분말, 샴피니온 분말 및 뽕잎 분말이 항산화작용 등 각 실시예에서 단독으로도 효과가 있지만 이들을 함께 투여할 경우 상승효과가 있는 것을 알 수 있다. As can be seen from the above examples, the invention, tahibo powder, champinion powder, and mulberry leaf powder is effective alone in each embodiment, such as antioxidant activity, but it can be seen that synergistic effect when administered together.
따라서 본 발명은 타히보 분말 20∼50 중량부와 샴피니온 분말 20∼50 중량부 및 뽕잎 분말 20∼50 중량부를 배합하여 제조된 것을 특징으로 하는 건강식품 조성물을 제공한다. 한편, 샴피니온 분말은 사탕수수를 짜고 남은 찌꺼기 또는 콩을 짜고 남은 찌꺼기를 60∼90일간 퇴비를 생산하는 단계; 상기 퇴비에 샴피니온균을 주입하여 30∼50일간 배양하는 단계; 상기 배양된 샴피니온을 채취하여 물로 세척한 후 2∼5cm 크기로 절단하는 단계; 상기 크기로 절단된 샴피니온을 건조기로 이송하여 45∼55℃로 8∼12시간 건조시키는 단계; 및 상기 건조된 샴피니온을 분쇄기로 이송하여 1.5mm의 본말로 분쇄하는 단계;를 거쳐 제조된다. Accordingly, the present invention provides a health food composition comprising 20 to 50 parts by weight of tahibo powder, 20 to 50 parts by weight of champinion powder, and 20 to 50 parts by weight of mulberry leaf powder. On the other hand, the champinion powder is squeezed sugar cane and the remaining residues or beans squeeze the remaining residues to produce a compost for 60 to 90 days; Injecting champinion bacteria into the compost and incubating for 30 to 50 days; Harvesting the cultured champinion and washing it with water and cutting it into 2-5 cm in size; Transferring the chopped champignion to a dryer to dry at 45 to 55 ° C. for 8 to 12 hours; And transferring the dried champinion to a grinder to grind it into a 1.5 mm original.
제1도는 Control군, 뽕잎 군, 타히보 군, 샴피니온 군 및 배합군의 혈청에 있어서의 퍼락시 래디칼(Peroxy Radical)에 대한 스카벤징(Scarvenging) 작용의 결과를 보여 주는 도표FIG. 1 is a chart showing the results of the scarvenging action on peroxy radicals in serum of the Control, Mulberry Leaf, Tahibo, Champignion and Combination groups.
제2도는 Control군, 뽕잎 군, 타히보 군, 샴피니온 군 및 배합군의 혈청에 있어서의 래디칼에 대한 항 산화 작용의 결과를 보여 주는 도표FIG. 2 is a chart showing the results of antioxidant activity on the radicals in serum of the Control group, Mulberry leaf group, Tahibo group, Champignion group and combination group.
제3도는 Control군, 뽕잎 군, 타히보 군, 샴피니온 군 및 배합군의 혈 중의 요소농도를 보여 주는 도표3 is a chart showing the blood urea concentrations of the control group, mulberry leaf group, Tahibo group, champinion group and combination group
제4도는 Control군, 뽕잎 군, 타히보 군, 샴피니온 군 및 배합군의 혈 중의 유산농도를 보여 주는 도표4 is a chart showing the lactic acid concentration in the blood of the control group, mulberry leaf group, Tahibo group, champinion group and combination group
제5도는 Control군, 뽕잎 군, 타히보 군, 샴피니온 군 및 배합군의 혈 중의 암모니아농도를 보여 주는 도표5 is a chart showing the ammonia concentration in the blood of the control group, mulberry leaf group, Tahibo group, champinion group and combination group
제6도는 Control군, 뽕잎 군, 타히보 군, 샴피니온 군 및 배합군의 소변 중 동 농도를 보여 주는 도표6 is a chart showing the copper concentration in the urine of the control group, mulberry leaf group, Tahibo group, champinion group and combination group
제7도는 Control군, 뽕잎 군, 타히보 군, 샴피니온 군 및 배합군의 소변 중 납 농도를 보여 주는 도표7 is a chart showing the lead concentration in the urine of the control group, mulberry leaf group, Tahibo group, champinion group and combination group
제8도는 Control군, 뽕잎 군, 타히보 군, 샴피니온 군 및 배합군의 소변 중 아연 농도를 보여 주는 도표FIG. 8 is a chart showing the concentration of zinc in the urine of the control group, mulberry leaf group, tahibo group, champinion group and combination group
제9도는 Control군, 뽕잎 군, 타히보 군, 샴피니온 군 및 배합군의 소변 중 카드뮴 농도를 보여 주는 도표Figure 9 is a chart showing the cadmium concentration in the urine of the control group, mulberry leaf group, Tahibo group, champinion group and combination group
제10도는 Control군, 뽕잎 군, 타히보 군, 샴피니온 군 및 배합군의 소변 중 마그네슘 농도를 보여 주는 도표10 is a chart showing the concentration of magnesium in the urine of the control group, mulberry leaf group, Tahibo group, champinion group and combination group
제11도는 뽕잎 군, 타히보 군, 샴피니온 군 및 배합군의 소변에 의한 나트륨의 농도를 보여 주는 도표FIG. 11 is a chart showing the concentration of sodium in the urine of mulberry leaf group, Tahibo group, champinion group and combination group
Claims (2)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080069867A KR101017556B1 (en) | 2008-07-18 | 2008-07-18 | Health food compositions included taheebo, champignon and mulberry leaves |
| JP2009010890A JP4802251B2 (en) | 2008-07-18 | 2009-01-21 | Health food composition made mainly of tahibo, champignon and mulberry leaves |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080069867A KR101017556B1 (en) | 2008-07-18 | 2008-07-18 | Health food compositions included taheebo, champignon and mulberry leaves |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20100009136A KR20100009136A (en) | 2010-01-27 |
| KR101017556B1 true KR101017556B1 (en) | 2011-02-28 |
Family
ID=41728798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020080069867A KR101017556B1 (en) | 2008-07-18 | 2008-07-18 | Health food compositions included taheebo, champignon and mulberry leaves |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP4802251B2 (en) |
| KR (1) | KR101017556B1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102670769A (en) * | 2011-03-18 | 2012-09-19 | 李启辉 | Tea lowering blood pressure and enabling all natural plants to serve as formula and preparation method thereof |
| JP6050678B2 (en) * | 2012-12-28 | 2016-12-21 | ポーラ化成工業株式会社 | Skin external preparation for hair |
| WO2019013374A1 (en) * | 2017-07-14 | 2019-01-17 | (주)뉴트리바이오텍 | Method for preparing freeze-dried product of taheebo ethanol extract |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09252746A (en) * | 1996-03-22 | 1997-09-30 | Nippon Kankyo Yakuhin Kk | Nutrient-supplementing food |
| KR20080092263A (en) * | 2007-04-10 | 2008-10-15 | 김국현 | Cox-2 and inos proteins expression inhibitor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02150239A (en) * | 1988-12-01 | 1990-06-08 | Shoichi Shimizu | Confectioneries containing 'tahibo' (tabebuia altisima) |
| JP2005034117A (en) * | 2003-07-14 | 2005-02-10 | Hokkaido Ekotekkusu Kk | Technique and method for utilization of compost recycled from waste such as food residue for bed (medium) culture of mushroom |
| JP2007330124A (en) * | 2006-06-13 | 2007-12-27 | Kenko Tsusho Kk | Health food composition for preventing and ameliorating obesity and lifestyle-related disease |
-
2008
- 2008-07-18 KR KR1020080069867A patent/KR101017556B1/en not_active IP Right Cessation
-
2009
- 2009-01-21 JP JP2009010890A patent/JP4802251B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09252746A (en) * | 1996-03-22 | 1997-09-30 | Nippon Kankyo Yakuhin Kk | Nutrient-supplementing food |
| KR20080092263A (en) * | 2007-04-10 | 2008-10-15 | 김국현 | Cox-2 and inos proteins expression inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4802251B2 (en) | 2011-10-26 |
| JP2010022359A (en) | 2010-02-04 |
| KR20100009136A (en) | 2010-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101532922B1 (en) | Biogas residue containing cow feed additive | |
| KR100934252B1 (en) | Its feed and an additive composition for poultry containing wild ginseng cultured root | |
| KR20190086421A (en) | Companion animal nutrient containing collagen extract and method for producing the same | |
| KR101956516B1 (en) | Chicken feed composition and preparing method thereof | |
| KR20200094979A (en) | Natural smell perfect lock and feed composition for companion animal containing the same | |
| KR101761377B1 (en) | Manufacturing method of chicken feed | |
| CN101953438B (en) | Flaky feed for feeding Geometridae insects | |
| CN1791419A (en) | Remedy | |
| KR101017556B1 (en) | Health food compositions included taheebo, champignon and mulberry leaves | |
| CN104543379A (en) | Plant extract contained pet feed with health care function and preparation method of pet feed | |
| KR101895733B1 (en) | Mixed feed for companion animals | |
| KR100911279B1 (en) | Feed mixture for replacing antibiotics | |
| KR101030569B1 (en) | Process for reducing cholesterol content and specific smell from meat of a goat using feedstuff comprising herves | |
| CN107307229B (en) | Feed additive for improving meat quality of rejected laying hens and preparation method and application thereof | |
| KR101902313B1 (en) | Composition of baby food and nourishing food for pet | |
| KR101341991B1 (en) | Korean cattle feed | |
| KR20090097727A (en) | Medical herb containing for korean cattle feed-composite and for livestock | |
| KR20190048125A (en) | Companion animal nutrient containing collagen extract and method for producing the same | |
| CN105104903B (en) | Broiler chickens mixed feed and preparation method thereof containing violet cabbage extract | |
| KR100902406B1 (en) | Feed for ell | |
| KR20060089201A (en) | The way of mulberry leaves stock raising | |
| KR101484274B1 (en) | Feed Composition Comprising Chestnut and Manufacturing Method Thereof | |
| KR20210087284A (en) | Manufacturing method of natural plant sulfur feed for raising sulfur duck | |
| JP2008230991A (en) | BIOLOGICALLY ACTIVE COMPOSITION ORIGINATED FROM SPARASSIS CRISPA Wulf:Fr. | |
| KR102281273B1 (en) | Pet food comprising fermented allium hookeri and method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20140121 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20150206 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20160218 Year of fee payment: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20170526 Year of fee payment: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20180212 Year of fee payment: 8 |
|
| LAPS | Lapse due to unpaid annual fee |